Stull, Stull & Brody Announces Class Action Lawsui

NEW YORK, July 21, 2017 (GLOBE NEWSWIRE) -- Stull, Stull & Brody ("SS&B") announces that a class action lawsuit was commenced in the United States District Court for the Southern District of Ohio on behalf of purchasers of Teva Pharmaceutical Industries Limited’s (“Teva”) American Depository Shares (“ADS”) (NYSE: TEVA ), between February 9, 2015 and November 3, 2016 (“Class Period”), in Teva’s voluntary and contributory employee benefit plans.  If you contributed money in any of Teva’s voluntary employee benefit plans and acquired Teva ADSs as a result of such contributions, your rights may be affected.

The complaint alleges, among other claims, that Teva’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to Teva’s business and its operational and financial results, and more specifically relating to Teva’s Foreign Corrupt Practices Act (“FCPA”) compliance and the alleged price fixing of generic drugs.    

If you have any questions concerning this notice or your rights or interests with respect to these matters, you may contact Michael Klein, Esq. of SS&B at  teva@ssbny.com , telephone 1-800-337-4983 x147, or by fax to 212-490-2022.

SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions.  SS&B has offices in New York and Beverly Hills.  SS&B’s website ( www.ssbny.com ) has additional information about the firm.

Attorney advertising.  Prior results do not guarantee a similar outcome.  This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.